{"filings":[{"id":860836,"accession_number":"0001104659-26-070501","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2026-06-04T20:04:26+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quoin Pharma gets Japan MHLW Orphan Drug Designation for QRX003 in Netherton Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Japan MHLW granted Orphan Drug Designation to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.","Designation provides incentives including up to 10 years of market exclusivity upon approval, priority review, and tax breaks.","Adds to prior U.S. FDA Orphan Drug, Pediatric Rare Disease, and Fast Track designations, plus EMA Orphan Drug Designation.","Quoin plans to self-commercialize QRX003 in Japan, U.S., and Western Europe; pivotal Phase 3 study expected H2 2026, NDA filing in 2027.","Company working with Japanese clinicians to refine clinical/regulatory pathway for approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94560,"accession_number":"0001104659-26-057140","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Q1 net loss $5M; FDA says single Phase 3 may suffice for QRX003","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.0M in Q1 2026 vs $3.8M in Q1 2025; cash $14M expected to fund operations into 2027.","FDA granted Fast Track Designation for QRX003 (Netherton Syndrome); Type C meeting indicated single Phase 3 may support U.S. approval.","Phase 3 patient recruitment on track to complete by end of 2026; potential NDA filing in 2027.","Japan MHLW confirmed QRX003 qualifies for Orphan Drug and Fast Track review; Saudi FDA Breakthrough Medicine Designation application filed.","QRX009 topical rapamycin platform advancing; planned IND submission for additional indication by Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107033,"accession_number":"0001104659-26-034951","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin raises up to $104.5M, advances QRX003 regulatory path, reports 2025 net loss $15.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement for up to $104.5M ($16.5M at closing, $88M warrant potential).","FDA grants Fast Track Designation; single Phase 3 study may suffice for NDA; plan to file in 2027.","Orphan Drug Designations for QRX003 in Netherton Syndrome in US and Europe; Rare Pediatric Disease Designation could yield $150-200M PRV.","Pediatric Netherton study expanded to 7 children with sustained skin healing, no adverse events; Peeling Skin study to 6 subjects.","Cash $18.7M at Dec 31, 2025; net loss Q4 $4.3M vs $2.3M YoY; full year $15.8M vs $9.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107032,"accession_number":"0001104659-26-026410","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants Fast Track Designation to Quoin's QRX003 for Netherton Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Fast Track Designation granted to QRX003 lotion (4%) for Netherton Syndrome, a rare genetic skin disorder with no approved treatments.","QRX003 is currently in two late-stage whole-body clinical trials evaluating safety and efficacy in Netherton Syndrome patients.","Previous designations include Orphan Drug Designation from FDA and EMA, and Pediatric Rare Disease Designation from FDA.","Fast Track enables more frequent FDA interactions, rolling review, and potential Accelerated Approval or Priority Review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107031,"accession_number":"0001104659-26-005127","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quoin seeks SFDA breakthrough designation; QRX003 could be first approved Netherton treatment in 2H2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed application with Saudi FDA for Breakthrough Medicine Designation for QRX003 for Netherton Syndrome.","If granted, QRX003 could be approved for sale/reimbursement in Saudi Arabia by 2H 2026, first-ever approved treatment for Netherton Syndrome.","Two pivotal trials for QRX003 lotion (4%) enrollment expected to complete 1H 2026; top-line data in 2H 2026.","NDA submission planned in US and other territories in late 2026/early 2027, subject to clinical outcomes.","As of Jan 20, 2026, Quoin has 1,616,179 ADSs outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123374,"accession_number":"0001104659-25-113237","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quoin Pharmaceuticals approves stock option award agreement forms under 2025 Equity Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Compensation Committee approved forms of Incentive and Non-Qualified Stock Option Award Agreements on Nov 14, 2025.","Awards are governed by the 2025 Equity Incentive Plan; exercise price can be paid via cash, broker-assisted sales, or cashless exercise.","Unvested options terminate upon employment cessation; vested options exercisable for up to 1 year after death/disability or 3 months after other termination.","All awards subject to clawback policy as per Plan Section 16.6; forfeited shares subject to transfer powers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123373,"accession_number":"0001104659-25-109802","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.","Clinical trial and stability batch manufacture to start Q4 2025; clinical testing in H1 2026.","Initial targets: Microcystic Lymphatic Malformations and Venous Malformations (no FDA-approved treatments).","CEO notes capital raise completed to fund Netherton Syndrome pivotal studies and advance rapamycin programs.","Milestone complements ongoing late-stage Netherton Syndrome and Peeling Skin Syndrome development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123372,"accession_number":"0001104659-25-107747","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Pharma reports Q3 net loss of $3.9M, raises up to $105.3M in private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.9M for Q3 2025 ($11.5M YTD) vs $2.3M and $6.7M in prior-year periods; R&D spend increased to $2.3M for Q3.","Cash, equivalents, and marketable securities totaled $5.4M as of Sept 30; Oct 2025 added $16.6M upfront from private placement, extending runway into 2027.","Private placement financing closed Oct 2025 with potential gross proceeds up to $105.3M including warrants exercise.","Sally Lawlor appointed CFO; FDA granted Orphan Drug Designation for QRX003 for Netherton Syndrome; pivotal studies to start Q4 2025.","NETHERTON NOW campaign surpassed 1.5M video views since Feb 2025; positive Peeling Skin Syndrome data released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123371,"accession_number":"0001104659-25-101269","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Quoin Pharmaceuticals receives FDA Orphan Drug Designation for QRX003 in Netherton Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Orphan Drug Designation to QRX003 for Netherton Syndrome; 7-year US exclusivity if approved.","Designation follows EMA Orphan Drug Designation granted in May 2025.","Two pivotal trials ongoing; enrollment completion expected Q1 2026, top-line data H2 2026, NDA submission later 2026.","QRX003 on track to become first approved treatment for Netherton Syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123370,"accession_number":"0001104659-25-099735","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Quoin raises $16.6M upfront in PIPE; up to $104.6M total with milestone warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds of $16.6M ($15M net) from private placement; proceeds for QRX003 development and general corporate.","Warrant series H, I, J, K with exercise prices $9.075-$12.375 per ADS; potential cash proceeds up to $88M if exercised.","Investors include AIGH Capital, Soleus Capital, Nantahala Capital, Diadema, Stonepine, ADAR1, Velan; director Langer invested $128k.","Warrant exercise triggers tied to FDA milestones for QRX003: Type C meeting, pivotal trial endpoints, FDA approval, or PRV sale.","Directors and officers subject to 180-day lock-up; proceeds with warrant exercise expected to fund operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140036,"accession_number":"0001104659-25-083248","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Quoin finalizes CFO exit: $433K lieu of notice, $108K bonus, extended options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation agreement signed August 21; effective August 15, 2025.","Dunn receives $433,620 in bi-weekly installments in lieu of 12 months' notice.","Additional $108,405 bonus for FY2024 paid in lump sum after 12 months.","Vested stock options post-termination exercise period extended to 1 year 9 months from 90 days.","Agreement includes mutual release of claims; no admission of liability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140035,"accession_number":"0001104659-25-081480","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["5.07","3.03","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Quoin shareholders approve increase in shares from 100M to 5B; Sally Lawlor named new CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized ordinary shares from 100,000,000 to 5,000,000,000 (50x).","Sally Lawlor appointed CFO effective Aug 18, 2025; base salary €380,000, bonus up to 50%, pension, health insurance.","Ms. Lawlor is the niece of CEO Dr. Michael Myers; prior roles at Sebela Pharma, Aptiv Plc, and KPMG.","Shareholders also approved new Compensation Policy and 2025 Equity Incentive Plan.","Prior CFO Gordon Dunn's last day was Aug 15, 2025; separation agreement pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140034,"accession_number":"0001104659-25-075244","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Pharma Q2 net loss $3.7M; QRX003 advances with FDA/EMA designations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $3.7M vs $2.0M YoY; cash $7.8M supports operations into Q1 2026.","Positive 6-month pediatric Netherton data: skin improvement, reduced itch, no adverse events.","FDA cleared second pivotal study (CL-QRX003-002); NDA filing targeted later 2026.","EMA granted Orphan Drug Designation; FDA granted Rare Pediatric Disease Designation for QRX003.","Positive 12-week Peeling Skin Syndrome data: improved disease severity and quality of life."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140033,"accession_number":"0001104659-25-066451","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Gordon Dunn to depart Quoin Pharmaceuticals; will continue until successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation agreed on July 3, 2025; CFO Gordon Dunn to leave later this year.","Mr. Dunn will continue in his role until his successor is appointed.","Separation agreement anticipated; will be filed as an exhibit to a future Form 8-K or periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157671,"accession_number":"0001104659-25-062406","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharma receives FDA Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Rare Pediatric Disease Designation (RPDD) on June 24, 2025 for QRX003.","QRX003 is Quoin's lead asset for treating Netherton Syndrome, a rare genetic disorder.","RPDD makes QRX003 eligible for priority review and a Rare Pediatric Disease Priority Review Voucher if approved.","Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases.","The designation underscores the unmet need in Netherton Syndrome with no approved therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157670,"accession_number":"0001104659-25-061184","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharmaceuticals sets 2025 AGM for August 21; shareholder proposal deadline June 30","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["2025 Annual General Meeting scheduled for August 21, 2025.","Shareholder proposals under Rule 14a-8 must be received by June 30, 2025.","Notice for proxy solicitations for director nominees other than company's must be given by June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157669,"accession_number":"0001104659-25-056378","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Quoin Pharma awards CEO $331k and COO $265k in 2024 cash bonuses","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee approved 2024 annual cash bonus of $331,238 for CEO Dr. Michael Myers.","COO Denise Carter received 2024 annual cash bonus of $264,640.","Bonuses are consistent with CEO and COO compensation programs approved at Dec 5, 2024 shareholder meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157668,"accession_number":"0001104659-25-052062","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Quoin Pharma gets FDA clearance to start second pivotal Netherton Syndrome study for QRX003","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared Study CL-QRX003-002, testing whole-body QRX003 (~80% BSA) with off-label systemic therapy in ~12-15 subjects.","Complements monotherapy pivotal study CL-QRX003-003 led by Dr. Amy Paller at Northwestern with up to 6 international sites.","Five U.S. sites open; sixth expected in June; all sites have subject cohorts ready for rapid enrollment.","Targets full recruitment into both pivotal studies by Q1 2026 and NDA filing later in 2026.","Quoin claims only company running two late-stage whole-body pivotal NS studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157667,"accession_number":"0001104659-25-051324","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Quoin Pharma gets EMA Orphan Drug Designation for QRX003 for Netherton Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA grants Orphan Drug Designation for QRX003, a topical treatment for Netherton Syndrome, a rare disease with no approved therapies.","ODD provides 10 years of market exclusivity in Europe upon approval, plus fee reductions and access to EU grants.","QRX003 is in multiple late-stage clinical trials; CEO cites skin healing and pruritus elimination in pediatric study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157666,"accession_number":"0001104659-25-048579","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Pharma Q1 net loss $3.8M; positive QRX003 data and patent expansion","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $11.6M at March 31, 2025; expected to fund operations into Q1 2026.","Net loss of $3.8M for Q1 2025, versus $2.3M in Q1 2024.","QRX003 showed reversal of clinical benefits upon discontinuation, confirming mechanism of action.","Patent applications filed for topical rapamycin and novel QRX003 formulations, extending IP to 2045.","FDA-cleared whole-body QRX003 study at Northwestern University for 8-12 Netherton patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157665,"accession_number":"0001104659-25-042661","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharma regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Compliance Notice on April 29, 2025 confirming minimum bid price compliance.","Closing bid price of ADSs was $1.00 or above for 10 consecutive trading days (April 9-28).","Nasdaq closed the matter; no further action required from company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157664,"accession_number":"0001104659-25-032189","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"Quoin Pharma approves 1-for-35 reverse ADS split effective April 9 to meet Nasdaq bid price rule","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1 ADS = 1 ordinary share to 1 ADS = 35 ordinary shares, effective April 9, 2025.","Reverse split aims to increase ADS price to comply with Nasdaq's $1.00 minimum bid price requirement.","Ordinary shares unaffected; new CUSIP for ADS will be 74907L409; ticker QNRX unchanged.","Holders of DRS and DTC ADSs need no action; certificated holders must surrender every 35 old ADSs for 1 new ADS.","Company cautions that it cannot guarantee the ratio change will achieve or maintain Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157663,"accession_number":"0001104659-25-032004","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["3.03"],"status":"ready","headline":"Quoin Pharma announces 1-for-20 reverse ADS split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changed from 1:1 to 1:20 (one ADS now represents 20 ordinary shares) effective April 8, 2025.","Reverse split automatically converts every 20 existing ADSs into 1 new ADS; ordinary shares unchanged.","New CUSIP number for ADSs is 74907L409; ticker QNRX remains on Nasdaq Capital Market.","Objective is to increase ADS per-share price above $1.00 minimum bid to avoid delisting.","Company cannot guarantee that the ratio change will achieve or sustain Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157662,"accession_number":"0001104659-25-031240","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharma reports positive clinical data for QRX003: skin healed, no adverse events in pediatric Netherton patient","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["After 6 weeks of daily whole-body QRX003, the pediatric Netherton patient's skin is almost completely healed.","Patient no longer requires antibiotics, antivirals, antihistamines, or glucocorticoids; pruritus eliminated.","Zero nightly sleep disturbances without sedating medication; first continuous uninterrupted sleep in patient's life.","No adverse events reported after 6 weeks of whole body treatment with QRX003.","Company expects to initiate whole body application on a second pediatric patient in a few weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176052,"accession_number":"0001104659-25-026176","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Quoin Pharmaceuticals replaces auditor Marcum LLP with CBIZ CPAs after attest business acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on March 18, 2025; CBIZ CPAs P.C. engaged effective immediately for FY 2025.","Change follows CBIZ CPAs' acquisition of Marcum's attest business effective November 1, 2024.","Marcum's FY 2023 and 2024 reports contained no adverse opinion, qualification, disagreements, or reportable events.","Engagement approved by Audit Committee; Marcum provided agreement letter attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176051,"accession_number":"0001104659-25-023447","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin reports FY2024 net loss $9.0M; cash $14.1M; positive QRX003 whole-body data in Netherton","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash of $14.1M at Dec 31, 2024 expected to fund operations into Q2 2026.","Net loss FY2024 $9.0M vs $8.7M; Q4 loss $2.3M vs $2.0M year ago.","First pediatric patient on whole-body QRX003 showed skin healing in 2 weeks, discontinued all prior meds, zero sleep disturbances.","FDA cleared whole-body QRX003 study; to be led by Dr. Amy Paller at Northwestern University.","Filed patent applications for topical rapamycin formulations targeting rare dermatological diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176050,"accession_number":"0001104659-25-018234","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharma: pediatric Netherton Syndrome patient shows dramatic skin healing after 2 weeks of QRX003","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IGA score improved from 7 to 1-2 (0-10 scale) after two weeks of whole-body QRX003 treatment.","Pruritus (itch) score reduced from 5 to 1; patient stopped all antihistamines, glucocorticoids, and antivirals.","Patient now experiences zero nightly sleep disturbances for first time; no adverse events reported.","First pediatric patient data from ongoing Investigator Pediatric Netherton Syndrome study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176049,"accession_number":"0001104659-25-009137","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin launches Netherton NOW campaign for rare disease awareness","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Campaign 'NETHERTON NOW' launched Feb 4, 2025 to raise awareness for Netherton Syndrome.","20% of babies with Netherton Syndrome estimated not to survive, per company.","Quoin has four ongoing clinical studies evaluating QRX003 for Netherton Syndrome.","As of Feb 4, 2025, outstanding ordinary shares (ADS) total 20,585,830."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176048,"accession_number":"0001104659-25-005619","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin reports reversal of QRX003 benefits 4 weeks post-discontinuation in Netherton syndrome study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["M-IASI score returned from 3 (12 weeks) to 18 at 4 weeks post-discontinuation, equaling baseline of 18.","WINRS (itch) worsened from 2 at 12 weeks to 8 post-discontinuation, exceeding baseline of 7.","IGA regressed from 'Almost Clear' at 12 weeks back to 'Moderate', same as baseline.","Data from first twice-daily dosed subject shows complete reversal of all clinical improvements after stopping QRX003."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176047,"accession_number":"0001104659-25-004132","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin reports positive QRX003 data in Netherton Syndrome: IGA improves from severe to mild after 6 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IGA score improved from 'severe' at baseline to 'mild' after six weeks of twice-daily QRX003 dosing.","After 12 days of dosing, IGA was 'mild-moderate'; full 6-week data confirms continued improvement.","Subject transitioned from 20% BSA treatment to whole-body application based on positive results.","No adverse events or safety concerns reported for this subject, consistent with prior studies.","Data from ongoing 12-week Investigator Pediatric Study supports QRX003's potential in Netherton Syndrome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176046,"accession_number":"0001104659-25-001350","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin reports Netherton Syndrome patient achieves near-clear skin after 12 weeks of QRX003 twice-daily","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["M-IASI score improved from 18 to 3; WINRS from 7 to 2; IGA from Moderate to Almost Clear after 12 weeks.","Patient satisfaction scores further improved from 6-week to 12-week mark; no safety concerns observed.","Data follows positive interim results announced Dec 2024; first subject completed full 12-week twice-daily dosing with QRX003.","Quoin is developing QRX003 for Netherton Syndrome, a rare genetic skin disorder with no approved therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192963,"accession_number":"0001104659-24-131554","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Quoin Pharmaceuticals prices $6.8M public offering of ADSs and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6.8M from offering of 15,111,110 ADSs (or pre-funded warrants) and Series F/G warrants at $0.45 per unit.","Series F warrants (2-yr expiry) and Series G warrants (5-yr expiry) each have exercise price of $0.45 per ADS.","Prior warrants for up to 7,002,500 ADSs amended: exercise price reduced to $0.45 from $1.60, expiry extended to Dec 2029.","Company officers and directors purchased ~$600K of ADSs and warrants in the offering.","Net proceeds to be used for general corporate purposes, including R&D and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192962,"accession_number":"0001104659-24-130017","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Quoin Pharma gets FDA clearance for whole-body QRX003 study in Netherton Syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA clearance for new Netherton Syndrome study of QRX003 applied to >80% BSA twice daily for 12 weeks in up to 8 patients.","Prior studies used ~20% BSA; new whole-body design mimics real-world use to support potential regulatory approval.","Study led by Dr. Amy Paller at Northwestern University; data to supplement QRX003 NDA package.","Quoin is a clinical-stage specialty pharma focused on rare/orphan diseases; stock trades as QNRX."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192961,"accession_number":"0001104659-24-127208","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["3.03","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Quoin shareholders approve charter amendments and executive compensation; board grants options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendments to Articles reducing quorum to 33 1/3% (25% for foreign private issuers) and aligning special meeting provisions.","CEO Myers: 2024 base $662,475, FY23 bonus $301,125, option for 536,603 ADSs at $0.78.","COO Carter: 2024 base $529,980, FY23 bonus $240,900, option for 536,609 ADSs at $0.78.","CFO Dunn: 2024 base $433,620, FY23 bonus $197,100, option for 338,994 ADSs at $0.78; non-employee directors each received option for 57,014 ADSs at $0.78."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192960,"accession_number":"0001104659-24-115850","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Q3 net loss $2.3M; initiates Peeling Skin Syndrome study; management buys shares","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.3M for Q3 2024 vs $1.9M in Q3 2023; nine-month net loss $6.7M vs $6.6M.","Cash and equivalents $10.3M as of Sept 30, 2024; expected to fund operations into late 2025.","Initiates investigator-led clinical study for QRX003 in Peeling Skin Syndrome in New Zealand; no approved treatments exist.","Opens two additional UK sites for Netherton Syndrome trials under FDA IND; plans further European expansion.","Entire management team made significant insider share purchases in September, signaling confidence in growth trajectory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192959,"accession_number":"0001104659-24-113085","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quoin Pharma gets Nasdaq bid-price extension to April 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq granted additional 180-day grace period until April 28, 2025 to regain $1.00 minimum bid price compliance.","Company met all other Nasdaq Capital Market initial listing requirements; may effect reverse split if needed.","If compliance not achieved by April 28, 2025, securities will be delisted, subject to appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209336,"accession_number":"0001104659-24-103867","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Quoin Pharma sets 2024 AGM for Dec 5; shareholder proposals due Oct 10","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for December 5, 2024, more than 30 days after last year's anniversary.","Shareholder proposals under Rule 14a-8 must be received by October 10, 2024 for inclusion in proxy.","Universal proxy rule notice for director nominees also due by October 10, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209335,"accession_number":"0001104659-24-089065","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin posts Q2 net loss of $2.0M; cash $12.6M; expands Netherton trials internationally","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $12.6M as of June 30, 2024; expected to fund operations into late 2025.","Net loss for Q2 2024 was $2.0M ($2.1M in Q2 2023); six-month net loss $4.3M ($4.7M in prior year).","Signed research agreement with University College Cork for topical rapamycin formulations using dissolvable microneedle technology.","Expanded Netherton Syndrome clinical trials to international sites starting with Saudi Arabia and EU.","Announced plans to initiate clinical study in Peeling Skin Syndrome, first site and patient identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227325,"accession_number":"0001104659-24-057008","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Quoin Pharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 29, 2024 for failing to maintain minimum bid price of $1.00 per ADS for 31 consecutive business days through April 26, 2024.","No immediate effect on listing; ADSs continue trading on Nasdaq Capital Market under symbol QNRX.","Company has 180 calendar days, until October 28, 2024, to regain compliance by having closing bid price >= $1.00 for at least 10 consecutive business days.","If not compliant by October 28, may be eligible for a second 180-day period if it meets other initial listing standards.","Company will monitor bid price and consider available options to cure the deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227324,"accession_number":"0001104659-24-045210","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Quoin shareholders approve issuance of shares to Alumni Capital LP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on April 5, 2024 approved Alumni Issuance Proposal.","Vote: 56,626 for, 23,469 against, 2,338 abstain; no broker non-votes.","Approval allows issuance of up to maximum ordinary shares (ADSs) per Jan 25, 2024 purchase agreement.","Alumni Capital LP is the counterparty; potential dilution from new share issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246203,"accession_number":"0001104659-24-033990","cik":1671502,"company_name":"Quoin Pharmaceuticals, Ltd.","ticker":"QNRX","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Quoin Pharma reports Q4/FY2023 net loss $8.7M; cash runway to H2 2025; positive QRX003 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $2.0M (flat YoY); FY2023 $8.7M vs $9.4M in 2022.","Cash & equivalents $10.7M as of Dec 31, 2023; plus $6.5M March 5 offering and $8M ELOC (pending shareholder approval).","Positive initial data from first 6 evaluable subjects: 5/6 had negligible/absent itch; all 6 showed skin score improvement.","No safety concerns reported in either ongoing Netherton Syndrome study; enrollment age lowered to 14+.","Expects cash runway to extend into H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":9806028.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}